Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
10/29/20 Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET
10/29/20 Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations
10/22/20 Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results
10/09/20 FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder
10/09/20 Trading in Alkermes Ordinary Shares Halted Today
Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

A preliminary proxy statement providing notification matters to be brought to a vote

A preliminary proxy statement providing notification matters to be brought to a vote

A preliminary proxy statement providing notification matters to be brought to a vote

A statement of beneficial ownership of common stock by certain persons

A statement of beneficial ownership of common stock by certain persons